Today's news from IZP.
Attention Business Editors:
INFLAZYME PHARMACEUTICALS LTD. EXECUTES AGREEMENT
WITH SCIREX CORPORATION TO MANAGE CLINICAL TRIALS ON
APANOL
VANCOUVER, Aug. 22 /CNW/ - Inflazyme Pharmaceuticals Ltd. (the
``Company'') announced today that it had officially selected SCIREX
Corporation of Hartford, Connecticut, as its Contract Research Organization to
format and manage the Company's Investigational New Drug (IND) Filing with the
U.S. Federal Drug Administration (FDA) for Apanol, Inflazyme's
state-of-the-art small molecule drug for combatting the causes and symptoms of
asthma.
SCIREX and its subsidiaries are among the leading organizations of their
type in the world, including among their clients such major pharmaceutical
companies as Pfizer & Co. and Johnson & Johnson.
SCIREX's specific responsibilities with regard to the Apanol IND Filing
will include: (1) reviewing all preclinical documentation; (2) formatting and
managing all FDA Filings; (3) providing guidance and advice throughout the
Filing Period in order to assure full compliance with all appropriate FDA
Standards; (4) recommending appropriate sources for the production of Apanol
of a sufficiently high quality and in sufficiently high quantities to
facilitate and sustain the Clinical Trials.
World-patented Apanol is the lead drug in Inflazyme's core platform
technology family of proprietary anti-inflammatory pharmaceuticals, which the
Company believes can ultimately replace most of the existing therapeutics
with which they will compete. Inflazyme's family of anti-inflammatory drugs
embodies the first completely novel class of anti-inflammatory drugs since the
discovery of NSAIDS in 1959. Inflazyme's compounds, known by the Group Name
IZP-94005, produce the same systemic anti-inflammatory results as steroids,
but without any of the pervasive negative side-effects, which steroids in so
many cases can generate. The Company anticipates that certain of its
proprietary family of drugs can eventually become therapeutics-of-choice for
the treatment of many diseases with the $28 billion world prescription
anti-inflammatory market.
Inflazyme Pharmaceuticals Ltd. is a mid-stage biopharmaceutical company
with a number of revolutionary drugs for the treatment of all types of
inflammatory diseases. Inflazyme's lead anti-inflammatory drugs are Apanol
for the treatment of asthma; Tiesole, an anti-allergy drug; and, Bispan for
the treatment of arthritis.
For more information on the Internet, including complete share price
updates (15 minutes delay), please go to: stockprofiles.com
For further information: James King, Manager of Investor Relations, (604) 733-5181 or (800)
315-3660
13:11e 22-AUG-96 |
